ArticleInvestigative ophthalmology & visual science2025
Epac1 Inhibits Orbital Fibroblast Activation to Ameliorate Thyroid-Associated Orbitopathy-Like Features Through the JAK/STAT Signaling Pathway.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Puerarin suppress adipogenesis and inflammation on orbital fibroblasts from patients with thyroid eye disease.Journal of endocrinological investigation · 2026Article
- Gypenosides attenuate HAmerican journal of translational research · 2026Article
- The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Orbital fibroblast (OF) activation plays an important role in thyroid-associated orbitopathy (TAO) development. Epac1, as a cyclic adenosine monophosphate (cAMP) effector, has been recognized as a pivotal mediator of the anti-fibrosis properties of cAMP. This study investigated the role and mechanisms of Epac1 in OF activation. Methods: Clinical orbital samples were collected from patients with TAO and normal healthy volunteers, and a TAO mouse model was established using adenovirus expressing the human TSHR A subunit (Ad-TSHR), which was evaluated for histopathological features and detected for Epac1 and vimentin expression levels. Clinical TAO samples- (TAO OFs) and healthy people-derived OFs (normal OFs) were isolated and identified using immunofluorescent (IF) staining. Healthy and TAO OFs were transfected with Epac1-overexpressing plasmid (Epac1) for Epac1 overexpression or sh-Epac1 plasmid for Epac1 knockdown, treated with TGFβ1, and then examined for cell phenotypes and the expression level of Epac1 and fibrosis-related markers (α-SMA, fibronectin, and collagens). Furthermore, adeno-associated virus (AAV) overexpressing Epac1 (AAV-Epac1) was injected into TAO mouse orbital tissues to investigate the anti-fibrotic effects of Epac1 on TGFβ1-stimulated OFs in vivo. Moreover, the phosphorylation of STAT3 in the TGFβ1-stimulated TAO OFs and TAO mice model was investigated. The JAK/STAT signaling inhibitor Stattic was used to explore the involvement of the JAK/STAT signaling in the functions of Epac1. Results: Both clinical TAO samples and the TAO mouse model demonstrated significantly changed histopathology, reduced Epac1 expression, and increased vimentin level. TGFβ1 stimulation significantly facilitated cell viability and migration of normal OFs and TAO OFs, and elevated α-SMA, fibronectin, vimentin, collagen I, and collagen III expression levels. However, Epac1 overexpression in OFs could notably attenuate these pro-fibrosis effects of TGFβ1 on both normal and TAO OFs, shown as inhibiting cell viability and migration and decreasing expression of fibrotic markers. Whereas, Epac1 knockdown aggravated TGFβ1-induced fibrosis. In vivo, Epac1 overexpression also improved TAO-like symptoms in TAO model mice. Mechanically, Epac1 overexpression inhibited STAT3 phosphorylation in vitro and in vivo. Stattic effectively attenuated the effects of Epac1 knockdown on TGFβ1-treated TAO OFs. Conclusions: Epac1 was a critical regulator of fibrotic and inflammatory processes in TAO through mediating the JAK/STAT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.